Detailansicht

Wissensnetz

Person

Ina Oehme (1974-)

Name	Ina Oehme
Zeit	1974- (Lebensdaten)
Ort	Heidelberg (Wirkungsort) Deutschland
Akademischer Grad bzw. Titel	PD Dr. phil. nat.
Beziehung	Universität Heidelberg. Medizinische Fakultät (Lehrbeauftragte) (2007-) Deutsches Krebsforschungszentrum (2005-)
Weitere Angaben	Diss. Chemische und pharmazeutische Wissenschaften, Studium der Ökotrophologie; Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center (DKFZ), und German Cancer Consortium (DKTK), Heidelberg; seit 2007 Lehrbeauftragte an der Medizinischen Fakultät der Universität Heidelberg
Datensatztyp	Person
GND-Nummer	129573388
Datensatz-ID	129573388
Beteiligt an alle anzeigen Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells Multi-Parametric Drug Screening identifies Vulnerabilities and Combination Treatment Strategies for Neuroblastoma Subtypes Specific Combination Therapy for H3K27M Pediatric Diffuse Midline Glioma Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow Advanced 3D cell culturing and monitoring system First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement ** Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement Transcriptional regulation of autophagy : identification of autophagy regulators as potential effectors of targeted therapy in neuroblastoma Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation HDAC8 : : a multifaceted target for therapeutic interventions Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat Zellzyklus- und Dichteabhängigkeit todesrezeptorvermittelter Apoptose und Untersuchungen des von RKO-Zellen konditionierten Mediums Zellzyklus- und Dichteabhängigkeit todesrezeptorvermittelter Apoptose und Untersuchungen des von RKO-Zellen konditionierten Mediums

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Ina Oehme (1974-)

Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours

Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells

Multi-Parametric Drug Screening identifies Vulnerabilities and Combination Treatment Strategies for Neuroblastoma Subtypes

Specific Combination Therapy for H3K27M Pediatric Diffuse Midline Glioma

Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow

Advanced 3D cell culturing and monitoring system

First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement **

Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity

Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement

Transcriptional regulation of autophagy : identification of autophagy regulators as potential effectors of targeted therapy in neuroblastoma

Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors

Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance

The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment

Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation

HDAC8 : : a multifaceted target for therapeutic interventions

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat

Zellzyklus- und Dichteabhängigkeit todesrezeptorvermittelter Apoptose und Untersuchungen des von RKO-Zellen konditionierten Mediums

Zellzyklus- und Dichteabhängigkeit todesrezeptorvermittelter Apoptose und Untersuchungen des von RKO-Zellen konditionierten Mediums